X4 Pharmaceuticals
XFOR | NASDAQ
$2.83
-$0.29 (-9.29%)
At close: Nov 16, 2026, 4:00 PM ET
$2.84
+$0.01 (+0.35%)
After-hours:
Nov 16, 2026, 7:30 PM ET
X4 Pharmaceuticals Company Profile
Company profile explainedCompany Profile
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| David H. Kirske | Chief Financial Officer, Treasurer & Corporate Secretary |
| John Volpone | President & Chief Operating Officer |
| Adam R. Craig | Executive Chair |
| Keith T. Flaherty | Founder & Member of Corporate Advisory Board |
| Renato T. Skerlj | Founder |
| Richard Peters | Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 8-K | Current Report |
| Oct 19, 2026 | 4 | Filing |
| Oct 08, 2026 | 8-K | Current Report |
| Oct 07, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 05, 2026 | 4 | Filing |
| Sep 21, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 09, 2026 | 8-K | Current Report |
| Sep 08, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
X4 Pharmaceuticals
| Country | United States |
| IPO Date | Nov 16, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 45 |
| CEO | Adam R. Craig |
Contact Details
61 North Beacon Street Boston,
Massachusetts 02134 United States
Stock Details
| Ticker Symbol | XFOR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001501697 |
| CUSIP Number | 98420X202 |
| ISIN Number | US98420X2027 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove XFOR